Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Solid Tumors 4Stomach Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Mesothelioma 1Liver Neoplasms 1Kidney Neoplasms 1Immune-related Adverse Events 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 2tocilizumab 1atezolizumab 1Immunoglobulin G 1Disulfides 1Dexamethasone 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nasopharyngeal Neoplasms × tocilizumab × Other solid neoplasm × Clear all
NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Terminated
61 enrolled 29 charts
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡